Scientific Visitor

The visiting scientist will contribute to research focused on the evaluation of chelators for radiopharmaceutical applications using terbium-161. The project aims to investigate the in vitro and in vivo stability of Tb-161–chelator complexes and to assess their suitability for the development of targeted radiopharmaceuticals.

During the research stay, the visiting scientist will participate in the conjugation of selected chelators to model biomolecules, followed by analytical characterization of the resulting bioconjugates. The conjugates will subsequently be radiolabelled with Tb-161 and subjected to a series of quality control, in vitro stability assesment and biodistribution studies. The primary objective is to evaluate how different chelator designs and conjugation strategies influence the stability of the radiometal complex under biologically relevant conditions.

The work will include radiolabelling experiments, analytical characterization, preparation of materials for in vivo evaluation, biodistribution studies in animal models, and quantification of radioactivity in collected tissues. Particular attention will be paid to indicators of radiometal release, such as accumulation in liver and bone, to assess the in vivo stability of the investigated Tb-161 complexes.

The generated data will be analyzed to compare the performance of the evaluated chelators and to identify promising approaches for future radiopharmaceutical development. Depending on project progress, the most promising chelator candidates may subsequently be investigated in combination with additional targeting vectors relevant to molecular imaging and targeted radionuclide therapy.